<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02372383</url>
  </required_header>
  <id_info>
    <org_study_id>14-1043</org_study_id>
    <secondary_id>UL1TR001082</secondary_id>
    <nct_id>NCT02372383</nct_id>
  </id_info>
  <brief_title>Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis</brief_title>
  <official_title>Pharmacokinetic Evaluation of Nontuberculous Mycobacterial Antibiotics in Cystic Fibrosis Versus Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Colorado Clinical &amp; Translational Sciences Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine antimycobacterial drug pharmacokinetics (PK) and&#xD;
      pharmacodynamics (PD) in patients with cystic fibrosis (CF) to improve treatment of&#xD;
      nontuberculous mycobacterial (NTM) lung disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine antimycobacterial drug pharmacokinetics (PK) and&#xD;
      pharmacodynamics (PD) in patients with cystic fibrosis (CF) to improve treatment of&#xD;
      nontuberculous mycobacterial (NTM) lung disease.&#xD;
&#xD;
      Aim 1: Determine the PK profile of oral antimycobacterial drugs (azithromycin, rifampin and&#xD;
      ethambutol) under both fasting conditions and when taken with food plus supplemental&#xD;
      pancreatic enzymes in subjects with pancreatic insufficient, compared to healthy controls.&#xD;
&#xD;
      Aim 2: Begin to investigate the influence of inflammation, host characteristics, and drug&#xD;
      metabolism on the PK of the antimycobacterial drugs.&#xD;
&#xD;
      Aim 3: Estimate an optimized dosing regimen for the antimycobacterial drugs against&#xD;
      Mycobacterium avium complex (MAC) using historic minimum inhibitory concentration (MIC) data&#xD;
      and models of Mycobacterium tuberculosis or MAC infection.&#xD;
&#xD;
      The central goal of this study is to improve treatment of NTM infection in CF. Upon&#xD;
      completion of this study the investigators will determine if and why PK of the&#xD;
      antimycobacterial drugs are altered in CF. More importantly, the investigators will develop&#xD;
      CF-specific guidelines to achieve therapeutic goals with recommendations for drug dosing&#xD;
      (including dose, dose frequency and timing in relation to meals and supplemental pancreatic&#xD;
      enzymes) and timing of therapeutic monitoring to be used for future treatment of NTM lung&#xD;
      disease in CF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Maximal Drug Concentration (Cmax)</measure>
    <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose</time_frame>
    <description>Cmax of the oral antimycobacterial drugs (azithromycin, rifampin and ethambutol) under both fasting conditions and when taken with food plus supplemental pancreatic enzymes in subjects with pancreatic insufficient CF, compared to healthy controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other PK Measures: Median Time to Maximal Drug Concentration (Tmax)</measure>
    <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose</time_frame>
    <description>Tmax of the oral antimycobacterial drugs (azithromycin, rifampin and ethambutol) under both fasting conditions and when taken with food plus supplemental pancreatic enzymes in subjects with pancreatic insufficient CF, compared to healthy controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other PK Measures: Half-life (t1/2)</measure>
    <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose</time_frame>
    <description>t1/2 of the oral antimycobacterial drugs (azithromycin, rifampin and ethambutol) under both fasting conditions and when taken with food plus supplemental pancreatic enzymes in subjects with pancreatic insufficient CF, compared to healthy controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other PK Measures: Drug Clearance</measure>
    <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose</time_frame>
    <description>drug clearance of the oral antimycobacterial drugs (azithromycin, rifampin and ethambutol) under both fasting conditions and when taken with food plus supplemental pancreatic enzymes in subjects with pancreatic insufficient CF, compared to healthy controls&#xD;
Reported here are the Median (range) CL in the CF fasting state compared to HC for Rifampin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other PK Measures: Volume of Distribution (Vd)</measure>
    <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose</time_frame>
    <description>Vd of the oral antimycobacterial drugs (azithromycin, rifampin and ethambutol) under both fasting conditions and when taken with food plus supplemental pancreatic enzymes in subjects with pancreatic insufficient CF, compared to healthy controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Covariates of PK Measures: C-reactive Protein (CRP)</measure>
    <time_frame>baseline</time_frame>
    <description>Median Concentration of C-reactive Protein. Begin to investigate the influence of inflammation, host characteristics, and drug metabolism on the PK of the antimycobacterial drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Covariates of PK Measures: Circulating Neutrophil Count</measure>
    <time_frame>baseline</time_frame>
    <description>Circulating neutrophil count. Begin to investigate the influence of inflammation, host characteristics, and drug metabolism on the PK of the antimycobacterial drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Covariates of PK Measures: Body Mass Index</measure>
    <time_frame>baseline</time_frame>
    <description>Body mass index (BMI). Begin to investigate the influence of inflammation, host characteristics, and drug metabolism on the PK of the antimycobacterial drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Covariates of PK Measures: Creatinine</measure>
    <time_frame>baseline</time_frame>
    <description>Creatinine. Begin to investigate the influence of inflammation, host characteristics, and drug metabolism on the PK of the antimycobacterial drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose</time_frame>
    <description>AUC of the oral antimycobacterial drugs (azithromycin, rifampin and ethambutol) under both fasting conditions and when taken with food plus supplemental pancreatic enzymes in subjects with pancreatic insufficient CF, compared to healthy controls.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Food/Enzymes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with CF will be given the antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy subjects without CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethambutol</intervention_name>
    <description>Anti-mycobacterial oral drug</description>
    <arm_group_label>Fasting</arm_group_label>
    <arm_group_label>Food/Enzymes</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <other_name>Myambutol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>Anti-mycobacterial oral drug</description>
    <arm_group_label>Fasting</arm_group_label>
    <arm_group_label>Food/Enzymes</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <other_name>Rifadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Anti-mycobacterial oral drug</description>
    <arm_group_label>Fasting</arm_group_label>
    <arm_group_label>Food/Enzymes</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pancrelipase</intervention_name>
    <description>Pancreatic enzyme replacement therapy</description>
    <arm_group_label>Food/Enzymes</arm_group_label>
    <other_name>Creon</other_name>
    <other_name>Zenpep</other_name>
    <other_name>Pertzye</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        CF Subject Inclusion Criteria:&#xD;
&#xD;
          -  CF diagnosis defined as a sweat chloride &gt;60mEq/L and/or the presence of two&#xD;
             disease-causing CFTR mutations.&#xD;
&#xD;
          -  Ages 16 years and above.&#xD;
&#xD;
          -  Pancreatic insufficient status defined as previous fecal pancreatic elastase &lt;100mcg/g&#xD;
             stool and/or having 2 disease-causing CFTR mutations known to be associated with&#xD;
             pancreatic insufficiency, and taking supplemental pancreatic enzymes between 1000-2500&#xD;
             lipase units/kg/meal.&#xD;
&#xD;
          -  No positive NTM cultures in the last 2 years.&#xD;
&#xD;
          -  Pulmonary function: Most recent FEV1 &gt; 40% predicted.&#xD;
&#xD;
          -  Willing to participate in and comply with the study procedures, and willingness of a&#xD;
             parent or legally authorized representative to provide written informed consent for&#xD;
             those subjects less than 18 years of age.&#xD;
&#xD;
        Healthy Control Inclusion Criteria:&#xD;
&#xD;
          -  Ages 18 years and above.&#xD;
&#xD;
          -  BMI below 30 to best match CF body type.&#xD;
&#xD;
          -  Willing to participate in and comply with the study procedures, and willingness of a&#xD;
             parent or legally authorized representative to provide written informed consent for&#xD;
             those subjects less than 18 years of age.&#xD;
&#xD;
        CF Subject Exclusion Criteria:&#xD;
&#xD;
          -  Allergy or intolerance to rifampin, ethambutol, or azithromycin.&#xD;
&#xD;
          -  Hepatic insufficiency defined as having an AST or ALT greater than three times the&#xD;
             upper limit of normal at the screening appointment.&#xD;
&#xD;
          -  Previous surgical bowel resection.&#xD;
&#xD;
          -  Previous lung transplant.&#xD;
&#xD;
          -  Use of medications known to interact with the antimycobacterial drug levels; of note,&#xD;
             the most common interactions in CF patients are the use of itraconazole, voriconazole,&#xD;
             and ivacaftor. We will have subjects hold H2 blockers and proton pump inhibitors for 3&#xD;
             days prior to each PK study day.&#xD;
&#xD;
          -  Inability to hold azithromycin: Subjects will not be excluded if they are on chronic&#xD;
             azithromycin for immunomodulatory purposes; however, we will ask that the subjects&#xD;
             hold the azithromycin starting at the screening visit, through a 2 week wash-out&#xD;
             period prior to Visit 2, and remain off through the end of Visit 3 (about 4 weeks&#xD;
             total).&#xD;
&#xD;
          -  Acute exacerbations: exclusion if any addition of oral, IV, or inhaled antibiotics, or&#xD;
             an acute gastrointestinal illness with vomiting or diarrhea in the 2 weeks prior to&#xD;
             each visit. No exclusion for previously prescribed alternating chronic inhaled or oral&#xD;
             antibiotics.&#xD;
&#xD;
          -  We will also exclude pregnant women (urine pregnancy test will be performed for&#xD;
             females on the day of each PK study) and decisionally challenged subjects.&#xD;
&#xD;
        Healthy Control Exclusion Criteria:&#xD;
&#xD;
          -  Allergy or intolerance to rifampin, ethambutol, or azithromycin.&#xD;
&#xD;
          -  Hepatic insufficiency defined as having an AST or ALT greater than three times the&#xD;
             upper limit of normal at the screening appointment.&#xD;
&#xD;
          -  Previous chronic GI disease or surgical bowel resection.&#xD;
&#xD;
          -  Use of medications known to interact with the antimycobacterial drug levels. We will&#xD;
             have subjects hold H2 blockers and proton pump inhibitors for 3 days prior to the PK&#xD;
             study day.&#xD;
&#xD;
          -  Acute illness: exclusion if respiratory illness requiring antibiotics or&#xD;
             gastrointestinal illness with vomiting or diarrhea in the 2 weeks prior to the PK&#xD;
             visit.&#xD;
&#xD;
          -  We will also exclude pregnant women (urine pregnancy test will be performed on the day&#xD;
             of PK study) and decisionally challenged subjects.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stacey Martiniano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Colroado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>February 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2015</study_first_posted>
  <results_first_submitted>November 26, 2019</results_first_submitted>
  <results_first_submitted_qc>January 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 11, 2021</results_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Nontuberculous Mycobacteria</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>20 CF subjects and 10 Healthy controls will be studied</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Healthy Controls (Fasting Only)</title>
          <description>Healthy subjects without CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug</description>
        </group>
        <group group_id="P2">
          <title>CF Patients, Fasting, Then Food</title>
          <description>Fasting for 1 day, then washout for 2 weeks, then Food for 1 day.&#xD;
Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg) Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg) Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg) Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Experimental: Food/Enzymes Subjects with CF will be given the antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg) Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg) Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg) Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose</description>
        </group>
        <group group_id="P3">
          <title>CF Patients, Food Then Fasting</title>
          <description>Food for 1 day, then washout for 2 weeks, then Fasting for 1 day.&#xD;
Subjects with CF will be given the antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg) Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg) Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg) Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg) Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg) Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg) Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unable to collect blood</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One patient was unable to participate at day 1 from the CF Subjects arm, and baseline data was not collected. Baseline demographics data was not stratified between the &quot;Fasting, then Food&quot; versus &quot;Food, then Fasting&quot; sequences. Baseline data was only collected for Healthy Controls versus CF subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>CF Subjects</title>
          <description>Fasting State Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug&#xD;
Food/Enzymes State Subjects with CF will then cross-over and be given the same dose of the 3 antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase). CF subjects will be randomized to either receive the medications in the Fasting or Food/Enzymes state first.</description>
        </group>
        <group group_id="B2">
          <title>Healthy Controls (Fasting Only)</title>
          <description>Healthy subjects without CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.3" lower_limit="16.1" upper_limit="24.8"/>
                    <measurement group_id="B2" value="25.3" lower_limit="18.2" upper_limit="30.7"/>
                    <measurement group_id="B3" value="20.6" lower_limit="16.1" upper_limit="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Maximal Drug Concentration (Cmax)</title>
        <description>Cmax of the oral antimycobacterial drugs (azithromycin, rifampin and ethambutol) under both fasting conditions and when taken with food plus supplemental pancreatic enzymes in subjects with pancreatic insufficient CF, compared to healthy controls.</description>
        <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy subjects without CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug</description>
          </group>
          <group group_id="O2">
            <title>CF Fasting</title>
            <description>Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug&#xD;
CF subjects will then cross-over following at least a 2 week washout time point and and be given the same dose of the 3 antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).</description>
          </group>
          <group group_id="O3">
            <title>CF Food</title>
            <description>Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug&#xD;
CF subjects will then cross-over following at least a 2 week washout time point and and be given the same dose of the 3 antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).</description>
          </group>
        </group_list>
        <measure>
          <title>Median Maximal Drug Concentration (Cmax)</title>
          <description>Cmax of the oral antimycobacterial drugs (azithromycin, rifampin and ethambutol) under both fasting conditions and when taken with food plus supplemental pancreatic enzymes in subjects with pancreatic insufficient CF, compared to healthy controls.</description>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rifampin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.56" lower_limit="10.2" upper_limit="27.0"/>
                    <measurement group_id="O2" value="12.5" lower_limit="6.6" upper_limit="21.9"/>
                    <measurement group_id="O3" value="11.2" lower_limit="4.7" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethambutol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.3" upper_limit="4.7"/>
                    <measurement group_id="O2" value="4.2" lower_limit="1.1" upper_limit="6.8"/>
                    <measurement group_id="O3" value="4.3" lower_limit="1.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Azithromycin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.6" upper_limit="2.1"/>
                    <measurement group_id="O2" value="2.0" lower_limit="0.1" upper_limit="5.3"/>
                    <measurement group_id="O3" value="2.2" lower_limit="0.1" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other PK Measures: Median Time to Maximal Drug Concentration (Tmax)</title>
        <description>Tmax of the oral antimycobacterial drugs (azithromycin, rifampin and ethambutol) under both fasting conditions and when taken with food plus supplemental pancreatic enzymes in subjects with pancreatic insufficient CF, compared to healthy controls</description>
        <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy subjects without CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug</description>
          </group>
          <group group_id="O2">
            <title>CF Patients, Fasting</title>
            <description>Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug&#xD;
CF subjects will then cross-over following at least a 2 week washout time point and and be given the same dose of the 3 antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).</description>
          </group>
          <group group_id="O3">
            <title>CF Patients, Food</title>
            <description>Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug&#xD;
CF subjects will then cross-over following at least a 2 week washout time point and and be given the same dose of the 3 antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).</description>
          </group>
        </group_list>
        <measure>
          <title>Other PK Measures: Median Time to Maximal Drug Concentration (Tmax)</title>
          <description>Tmax of the oral antimycobacterial drugs (azithromycin, rifampin and ethambutol) under both fasting conditions and when taken with food plus supplemental pancreatic enzymes in subjects with pancreatic insufficient CF, compared to healthy controls</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rifampin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O3" value="2.5" lower_limit="1" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethambutol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="2.3" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Azithromycin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other PK Measures: Half-life (t1/2)</title>
        <description>t1/2 of the oral antimycobacterial drugs (azithromycin, rifampin and ethambutol) under both fasting conditions and when taken with food plus supplemental pancreatic enzymes in subjects with pancreatic insufficient CF, compared to healthy controls</description>
        <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy subjects without CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug</description>
          </group>
          <group group_id="O2">
            <title>CF Fasting</title>
            <description>Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug&#xD;
CF subjects will then cross-over following at least a 2 week washout time point and and be given the same dose of the 3 antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).</description>
          </group>
          <group group_id="O3">
            <title>CF Food</title>
            <description>Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug&#xD;
CF subjects will then cross-over following at least a 2 week washout time point and and be given the same dose of the 3 antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).</description>
          </group>
        </group_list>
        <measure>
          <title>Other PK Measures: Half-life (t1/2)</title>
          <description>t1/2 of the oral antimycobacterial drugs (azithromycin, rifampin and ethambutol) under both fasting conditions and when taken with food plus supplemental pancreatic enzymes in subjects with pancreatic insufficient CF, compared to healthy controls</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rifampin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="2.6" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3.4" lower_limit="2.2" upper_limit="5.9"/>
                    <measurement group_id="O3" value="3.4" lower_limit="2.3" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethambutol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="3.3" upper_limit="6.0"/>
                    <measurement group_id="O2" value="4.3" lower_limit="3.1" upper_limit="7.2"/>
                    <measurement group_id="O3" value="4.7" lower_limit="3.0" upper_limit="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Azithromycin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="3.3" upper_limit="7.0"/>
                    <measurement group_id="O2" value="5.2" lower_limit="2.5" upper_limit="14.0"/>
                    <measurement group_id="O3" value="6.6" lower_limit="2.5" upper_limit="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other PK Measures: Drug Clearance</title>
        <description>drug clearance of the oral antimycobacterial drugs (azithromycin, rifampin and ethambutol) under both fasting conditions and when taken with food plus supplemental pancreatic enzymes in subjects with pancreatic insufficient CF, compared to healthy controls&#xD;
Reported here are the Median (range) CL in the CF fasting state compared to HC for Rifampin.</description>
        <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy subjects without CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug</description>
          </group>
          <group group_id="O2">
            <title>CF Fasting</title>
            <description>Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug&#xD;
CF subjects will then cross-over following at least a 2 week washout time point and and be given the same dose of the 3 antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).</description>
          </group>
          <group group_id="O3">
            <title>CF Food</title>
            <description>Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug&#xD;
CF subjects will then cross-over following at least a 2 week washout time point and and be given the same dose of the 3 antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).</description>
          </group>
        </group_list>
        <measure>
          <title>Other PK Measures: Drug Clearance</title>
          <description>drug clearance of the oral antimycobacterial drugs (azithromycin, rifampin and ethambutol) under both fasting conditions and when taken with food plus supplemental pancreatic enzymes in subjects with pancreatic insufficient CF, compared to healthy controls&#xD;
Reported here are the Median (range) CL in the CF fasting state compared to HC for Rifampin.</description>
          <units>L/h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rifampin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="3.8" upper_limit="8.5"/>
                    <measurement group_id="O2" value="7.9" lower_limit="3.6" upper_limit="15.7"/>
                    <measurement group_id="O3" value="7.6" lower_limit="4.4" upper_limit="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethambutol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3" lower_limit="34.3" upper_limit="61.8"/>
                    <measurement group_id="O2" value="42.4" lower_limit="23.6" upper_limit="156.6"/>
                    <measurement group_id="O3" value="37.3" lower_limit="27.7" upper_limit="185.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Azithromycin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6" lower_limit="40.3" upper_limit="190.9"/>
                    <measurement group_id="O2" value="73.6" lower_limit="31.9" upper_limit="978.8"/>
                    <measurement group_id="O3" value="82.8" lower_limit="41.7" upper_limit="567.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other PK Measures: Volume of Distribution (Vd)</title>
        <description>Vd of the oral antimycobacterial drugs (azithromycin, rifampin and ethambutol) under both fasting conditions and when taken with food plus supplemental pancreatic enzymes in subjects with pancreatic insufficient CF, compared to healthy controls</description>
        <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy subjects without CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug</description>
          </group>
          <group group_id="O2">
            <title>CF Fasting</title>
            <description>Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug&#xD;
CF subjects will then cross-over following at least a 2 week washout time point and and be given the same dose of the 3 antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).</description>
          </group>
          <group group_id="O3">
            <title>CF Food</title>
            <description>Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug&#xD;
CF subjects will then cross-over following at least a 2 week washout time point and and be given the same dose of the 3 antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).</description>
          </group>
        </group_list>
        <measure>
          <title>Other PK Measures: Volume of Distribution (Vd)</title>
          <description>Vd of the oral antimycobacterial drugs (azithromycin, rifampin and ethambutol) under both fasting conditions and when taken with food plus supplemental pancreatic enzymes in subjects with pancreatic insufficient CF, compared to healthy controls</description>
          <units>L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rifampin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3" lower_limit="16.4" upper_limit="39.0"/>
                    <measurement group_id="O2" value="39.7" lower_limit="21.3" upper_limit="67.5"/>
                    <measurement group_id="O3" value="37.4" lower_limit="25.9" upper_limit="105.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethambutol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352.8" lower_limit="162.0" upper_limit="453.0"/>
                    <measurement group_id="O2" value="274.6" lower_limit="139.7" upper_limit="1045.9"/>
                    <measurement group_id="O3" value="354.3" lower_limit="147.3" upper_limit="1866.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Azithromycin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="717.0" lower_limit="406.1" upper_limit="1083.4"/>
                    <measurement group_id="O2" value="549.2" lower_limit="201.5" upper_limit="9503.5"/>
                    <measurement group_id="O3" value="621.3" lower_limit="249.3" upper_limit="8608.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Covariates of PK Measures: C-reactive Protein (CRP)</title>
        <description>Median Concentration of C-reactive Protein. Begin to investigate the influence of inflammation, host characteristics, and drug metabolism on the PK of the antimycobacterial drugs.</description>
        <time_frame>baseline</time_frame>
        <population>This Outcome Measure was only analyzed at the Fasting period and was not collected during the Food period of the study. Therefore, 0 participants are analyzed for the &quot;CF Food&quot; arm for this Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy subjects without CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug</description>
          </group>
          <group group_id="O2">
            <title>CF Fasting</title>
            <description>Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug&#xD;
CF subjects will then cross-over following at least a 2 week washout time point and and be given the same dose of the 3 antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).</description>
          </group>
          <group group_id="O3">
            <title>CF Food</title>
            <description>Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug&#xD;
CF subjects will then cross-over following at least a 2 week washout time point and and be given the same dose of the 3 antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).</description>
          </group>
        </group_list>
        <measure>
          <title>Covariates of PK Measures: C-reactive Protein (CRP)</title>
          <description>Median Concentration of C-reactive Protein. Begin to investigate the influence of inflammation, host characteristics, and drug metabolism on the PK of the antimycobacterial drugs.</description>
          <population>This Outcome Measure was only analyzed at the Fasting period and was not collected during the Food period of the study. Therefore, 0 participants are analyzed for the &quot;CF Food&quot; arm for this Outcome Measure.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.2" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Covariates of PK Measures: Circulating Neutrophil Count</title>
        <description>Circulating neutrophil count. Begin to investigate the influence of inflammation, host characteristics, and drug metabolism on the PK of the antimycobacterial drugs</description>
        <time_frame>baseline</time_frame>
        <population>This Outcome Measure was only analyzed at the Fasting period and was not collected during the Food period of the study. Therefore, 0 participants are analyzed for the &quot;CF Food&quot; arm for this Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy subjects without CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug</description>
          </group>
          <group group_id="O2">
            <title>CF Fasting</title>
            <description>Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug&#xD;
CF subjects will then cross-over following at least a 2 week washout time point and and be given the same dose of the 3 antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).</description>
          </group>
          <group group_id="O3">
            <title>CF Food</title>
            <description>Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug&#xD;
CF subjects will then cross-over following at least a 2 week washout time point and and be given the same dose of the 3 antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).</description>
          </group>
        </group_list>
        <measure>
          <title>Covariates of PK Measures: Circulating Neutrophil Count</title>
          <description>Circulating neutrophil count. Begin to investigate the influence of inflammation, host characteristics, and drug metabolism on the PK of the antimycobacterial drugs</description>
          <population>This Outcome Measure was only analyzed at the Fasting period and was not collected during the Food period of the study. Therefore, 0 participants are analyzed for the &quot;CF Food&quot; arm for this Outcome Measure.</population>
          <units>10^3 cells/uL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="1.4" upper_limit="7.2"/>
                    <measurement group_id="O2" value="3.8" lower_limit="2.5" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Covariates of PK Measures: Body Mass Index</title>
        <description>Body mass index (BMI). Begin to investigate the influence of inflammation, host characteristics, and drug metabolism on the PK of the antimycobacterial drugs</description>
        <time_frame>baseline</time_frame>
        <population>This Outcome Measure was only analyzed at the Fasting period and was not collected during the Food period of the study. Therefore, 0 participants are analyzed for the &quot;CF Food&quot; arm for this Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy subjects without CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug</description>
          </group>
          <group group_id="O2">
            <title>CF Fasting</title>
            <description>Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug&#xD;
CF subjects will then cross-over following at least a 2 week washout time point and and be given the same dose of the 3 antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).</description>
          </group>
          <group group_id="O3">
            <title>CF Food</title>
            <description>Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug&#xD;
CF subjects will then cross-over following at least a 2 week washout time point and and be given the same dose of the 3 antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).</description>
          </group>
        </group_list>
        <measure>
          <title>Covariates of PK Measures: Body Mass Index</title>
          <description>Body mass index (BMI). Begin to investigate the influence of inflammation, host characteristics, and drug metabolism on the PK of the antimycobacterial drugs</description>
          <population>This Outcome Measure was only analyzed at the Fasting period and was not collected during the Food period of the study. Therefore, 0 participants are analyzed for the &quot;CF Food&quot; arm for this Outcome Measure.</population>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" lower_limit="18.9" upper_limit="25.1"/>
                    <measurement group_id="O2" value="21.9" lower_limit="18.0" upper_limit="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Covariates of PK Measures: Creatinine</title>
        <description>Creatinine. Begin to investigate the influence of inflammation, host characteristics, and drug metabolism on the PK of the antimycobacterial drugs</description>
        <time_frame>baseline</time_frame>
        <population>This Outcome Measure was only analyzed at the Fasting period and was not collected during the Food period of the study. Therefore, 0 participants are analyzed for the &quot;CF Food&quot; arm for this Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy subjects without CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug</description>
          </group>
          <group group_id="O2">
            <title>CF Fasting</title>
            <description>Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug&#xD;
CF subjects will then cross-over following at least a 2 week washout time point and and be given the same dose of the 3 antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).</description>
          </group>
          <group group_id="O3">
            <title>CF Food</title>
            <description>Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug&#xD;
CF subjects will then cross-over following at least a 2 week washout time point and and be given the same dose of the 3 antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).</description>
          </group>
        </group_list>
        <measure>
          <title>Covariates of PK Measures: Creatinine</title>
          <description>Creatinine. Begin to investigate the influence of inflammation, host characteristics, and drug metabolism on the PK of the antimycobacterial drugs</description>
          <population>This Outcome Measure was only analyzed at the Fasting period and was not collected during the Food period of the study. Therefore, 0 participants are analyzed for the &quot;CF Food&quot; arm for this Outcome Measure.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.8" upper_limit="1.2"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.7" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC)</title>
        <description>AUC of the oral antimycobacterial drugs (azithromycin, rifampin and ethambutol) under both fasting conditions and when taken with food plus supplemental pancreatic enzymes in subjects with pancreatic insufficient CF, compared to healthy controls.</description>
        <time_frame>0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy subjects without CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug</description>
          </group>
          <group group_id="O2">
            <title>CF Fasting</title>
            <description>Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug&#xD;
CF subjects will then cross-over following at least a 2 week washout time point and and be given the same dose of the 3 antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).</description>
          </group>
          <group group_id="O3">
            <title>CF Food</title>
            <description>Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug&#xD;
CF subjects will then cross-over following at least a 2 week washout time point and and be given the same dose of the 3 antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC)</title>
          <description>AUC of the oral antimycobacterial drugs (azithromycin, rifampin and ethambutol) under both fasting conditions and when taken with food plus supplemental pancreatic enzymes in subjects with pancreatic insufficient CF, compared to healthy controls.</description>
          <units>mg*h/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rifampin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.3" lower_limit="70.5" upper_limit="156"/>
                    <measurement group_id="O2" value="76" lower_limit="38.1" upper_limit="167.5"/>
                    <measurement group_id="O3" value="79.2" lower_limit="30.8" upper_limit="136.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethambutol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" lower_limit="16.2" upper_limit="30.4"/>
                    <measurement group_id="O2" value="21.8" lower_limit="6.4" upper_limit="38.2"/>
                    <measurement group_id="O3" value="23.6" lower_limit="5" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Azithromycin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="2.6" upper_limit="12.4"/>
                    <measurement group_id="O2" value="6.8" lower_limit="0.5" upper_limit="15.7"/>
                    <measurement group_id="O3" value="6" lower_limit="0.9" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the time of participation in the study, about 6 weeks.</time_frame>
      <desc>Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. One participant is included in the Fasting arm who dropped out immediately after, prior to the Food period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Healthy Controls</title>
          <description>Healthy subjects without CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug</description>
        </group>
        <group group_id="E2">
          <title>CF Patients, Fasting</title>
          <description>Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug&#xD;
CF subjects will then cross-over following at least a 2 week washout time point and and be given the same dose of the 3 antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).</description>
        </group>
        <group group_id="E3">
          <title>CF Patients, Food</title>
          <description>Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes&#xD;
Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)&#xD;
Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)&#xD;
Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)&#xD;
Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose&#xD;
Ethambutol: Anti-mycobacterial oral drug&#xD;
Rifampin: Anti-mycobacterial oral drug&#xD;
Azithromycin: Anti-mycobacterial oral drug&#xD;
CF subjects will then cross-over following at least a 2 week washout time point and and be given the same dose of the 3 antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Stacey Martiniano</name_or_title>
      <organization>UColorado</organization>
      <phone>7207776181</phone>
      <email>stacey.martiniano@childrenscolorado.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

